Great Britain has approved the world’s first pill to treat Covit-19
For the first time, a drug against Govit-19 has been approved, which can be taken orally and intended to prevent severe studies. Molnupiravir was first used in the UK. Approval in the EU may continue.
D.The British pharmaceutical company has approved the MHRA Kovid-19 treatment pill for the first time. The antiviral drug Lagevrio (also known as molnupravir) is safe and effective in reducing the risk of hospitalization and death of covit patients with mild and moderate cases, the British government said in a statement on Thursday. It is the world’s first approved antiviral drug for oral use against Govit-19. The drug does not need to be administered by cannulas or intravenous infusions.
The product, developed by pharmaceutical companies Ridgeback Biotherapeutics and Merck Sharp & Dohme (MSD), interferes with the reproduction of the virus, thus reducing the severity of the disease. Clinical studies show that it is most effective when taken as soon as possible after a positive test and within five days of the onset of symptoms.
Health Minister Sajid Javed hailed the approval as a “historic day for our country” and a “decisive game” for risk groups such as those with a repressed immune system. MSD has applied for approval in the United States, the European Union and other countries. The European Pharmaceuticals Agency (EMA) announced in late October that it was examining the use of molnupravir. The US FDA has also begun the approval process for the product. EMA is also examining seven other corona funds.
The American company Guillotine Remdecivir (brand name Vecluri) has been approved in the EU since July 2020 – but only for some seriously ill corona patients. It is given as an infusion. A tablet that can alleviate the symptoms of corona virus and recover quickly and can be taken at home will be a turning point in the fight against corona virus.
It combines prevention and vaccination with treatment for infections. Corona virus outbreaks may be reduced in poorer countries where hospitals have to treat fewer patients and have poor health facilities.
Initially, however, funding will be limited. MSD expects to be able to produce ten million units by the end of this year. Most of these have already been mandated by governments around the world.
“Social media maven. Amateur food buff. Pop culture trailblazer. Tv ninja.”